AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its ...

AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Nov 11 (Reuters) - AbbVie (ABBV.N), opens new tab shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening ...

AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of ...